Alzheimer's disease: Immunity and diagnosis;Enfermedad de Alzheimer: Inmunidad y diagnóstico

Revista de Neurologia

Volumn 51, Issue 3, 2010, Pages 153-164

  Herrera Rivero, Marisol ^a   Hernández Aguilar, María Elena ^a   Manzo, Jorge ^a   Aranda Abreu, Gonzalo Emiliano ^a  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Beta amyloid; Biomarkers; Lymphocytes; Peripheral immune response; Secretases; Tau

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; GAMMA SECRETASE; TAU PROTEIN; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BIOLOGICAL MARKER; SECRETASE;

ALZHEIMER DISEASE; DIAGNOSTIC ACCURACY; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INFORMATION; REVIEW; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; BIOLOGICAL MARKERS; HUMANS; RISK FACTORS; TAU PROTEINS;

EID: 77955637289     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5103.2009531     Document Type: Review

References (74)

1. Morelli L, Castaño E. Proteínas anormales en la enfermedad de Alzheimer. CienciaHoy 2008; 7: 41 [online]. URL: http://www.cienciahoy.org. ar/hoy41/protei1.htm. [16.06.2008].
2. De la Vega R, Zambrano A. Alzheimer. La circunvalación del hipocampo [online]. URL: http://www.hipocampo.org/alzheimer.asp. [16.06.2008].
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
4. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-62.
5. Mecocci P, Polidori MC. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer's disease. Arch Neurol 2002; 59: 794-8.
6. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56: 321-39.
7. Jarrett JT, Berger EP, Landsbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7.
8. Alzheimer's Society. URL: http://www.alzheimers.org.uk/site/scripts/ documents-info.php?documentID=100.
9. Alzheimer's Association. URL: http://www.alz.org/alzheimers-disease- standard-prescriptions.asp.
10. Johnson GVW, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. J Alzheimers Dis 1999; 1: 329-51.
11. Rossi G, Dalprà L, Crosti F, Lissoni S, Sciacca FL, Catania M, et al. A new function of microtubule-associated protein tau: Involvement in chromosome stability. Cell Cycle 2008; 7: 1788-94.
12. García T, Jay D. Fosforilación de tau y enfermedad de Alzheimer. Gac Med Mex 2004; 140: 329-33.
13. Thurston VC, Zinkowski RP, Binder LI. Tau as a nucleolar protein in human nonneural cells in vitro and in vivo. Chromosoma 1996; 105: 20-30.
14. Wikipedia. URL: http://en.wikipedia.org/wiki/Tau-protein.
15. Patrick GN, Zukerberg L, Nikolic M, De la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999; 402: 615-22.
16. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-72.
17. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008; 283: 29615-9.
18. Haass C, Hung AY, Selkoe DJ. Processing of β-amyloid precursor protein in microglia and astrocytes favors a localization in internal vesicles over constitutive secretion. J Neurosci 1991; 11: 3783-93.
19. Yamazaki T, Selkoe DJ, Koo EH. Trafficking of cell surface β-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol 1995; 129: 431-42.
20. Tabaton M, Piccini A. Role of water-soluble amyloid-β in the pathogenesis of Alzheimer's disease. Int J Exp Path 2005; 86: 139-45.
21. Sisodia SS. β-amyloid precursor protein cleavage by a membrane-bound portease. Proc Natl Acad Sci U S A 1992; 89: 6075-9.
22. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23: 105-14.
23. Hung AY, Koo EH, Haass C, Selkoe DJ. Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. Proc Natl Acad Sci U S A 1992; 89: 9439-43.
24. Muresan V, Varvel MH, Lamb BT, Muresan Z. The cleavage products of amyloid-β precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci 2009; 29: 3565-78.
25. Chan SL, Furukawa K, Mattson MP. Presenilins and APP in neuritic and synaptic plasticity: Implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med 2002; 2: 167-96.
26. Vassar R, Cole SL. The Alzheimer's disease β-secretase enzime, BACE1. Mol Neurodegener 2007; 2: 22.
27. Creemers JW, Inés-Domínguez D, Plets E, Serneels L, Taylor NA, Multhaup G, et al. Processing of β-secretase by furin and other members of the proprotein convertase family. J Biol Chem 2001; 276: 4211-7.
28. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, et al. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005; 280: 36815-23.
29. Morais VA, Leight S, Pijak DS, Lee VMY, Costa J. Cellular localization of nicastrin affects amyloid β species production. FEBS Lett 2008; 582: 427-33.
30. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. Cell 2007; 131: 215-21.
31. Dun-Sheng Y, Tandon A. Mature glycosilation and trafficking of nicastrin modulate its binding to presenilins. J Biol Chem 2002; 207: 28135-42.
32. Zhang J, Kang DE, Xia W, Okochi M, Mori H, Selkoe DJ, et al. Subcellular distribution and turnover of presenilins in transfected cells. J Biol Chem 1998; 273: 12436-42.
33. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacaná E, Sunderland T, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274: 1710-3.
34. Palacino JJ, Berechid BE, Alexander P, Eckman C, Younkin S, Nye JS, et al. Identification and characterization of presenilin-independent Notch signaling. J Biol Chem 2000; 275: 215-22.
35. Cao X, Sudhof TC. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 2004; 279: 24601-11.
36. McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv 2001; 1: 22-9.
37. Yasojima K, Schwab C, McGeer EG, McGeer PL. Upregulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 1999; 154: 927-36.
38. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer's disease. Neuromolecular Med 2005; 7: 255-64.
39. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005; 5: 243-51.
40. Padgett DA, Glaser R. How stress influences the immune response. Trends Immunol 2003; 24: 444-8.
41. Irizarry MC. Biomarkers of Alzheimer disease in plasma. J Am Soc Exp Neurother 2004; 1: 226-34.
42. Combarros O, Álvarez-Arcaya A, Sánchez-Guerra M, Infante J, Berciano J. Candidate gene association studies in sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14: 41-54. (Pubitemid 34621580)
43. Ashford JW. APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 2004; 23: 157-65.
44. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90: 9649-53.
45. Cedazo-Mínguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007; 11: 1227-38.
46. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92: 12260-4.
47. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 2004; 101: 2070-5.
48. Chen S, Bawa D, Besshoh S, Gurd JW, Brown IR. Association of heat shock proteins and neuronal membrane components with lipid rafts from the rat brain. J Neurosci Res 2005; 81: 522-9.
49. Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipo protein E signaling in primary neurons. J Neurochem 2005; 93: 145-55.
50. Jellinger KA, Janetzky B, Attems J, Kienzl E. Biomarkers for early diagnosis of Alzheimer disease: Alzheimer Associated gene -a new blood biomarker? J Cell Mol Med 2008; 12: 1094-117.
51. Nagga K, Gottfries J, Blennow K, Marcusson J. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord 2002; 14: 183-90.
52. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-103.
53. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 718-26.
54. Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999; 52: 562-5.
55. McIntyre JA, Chapman J, Shavit E, Hamilton RL, Dekosky ST. Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies. Autoimmunity 2007; 40: 390-6.
56. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
57. Kim DK, Seo MY, Lim SW, Kim S, Kim JW, Carrol BJ, et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacology 2001; 25: 84-90.
58. Hooper C, Lovestone S, Sainz-Fuertes R. Alzheimer's disease, diagnosis and the need for biomarkers. Biomarker Insights 2008; 3: 317-23.
59. Leuner K, Pantel J, Frey C, Schindowski K, Schulz K, Wegat T, et al. Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. J Neural Transm 2007; 72: 207-15.
60. Fernández-Verdecia CI, Díaz del Guante MA, Castillo-Díaz L, Álvarez-Blanco J. Neurogénesis como diana terapéutica para la enfermedad de Alzheimer. Rev Neurol 2009; 49: 193-201.
61. Jiménez del Río M, Vélez-Pardo C. Los linfocitos: modelo de estudio en las enfermedades de Alzheimer y Parkinson. IATREIA 2006; 19: 47-61.
62. De las Cuevas N, Muñoz U, Hermida OG, Martín-Requero A. Altered transcripcional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol Aging 2005; 26: 615-24.
63. Schindowski K, Eckert A, Peters J, Gorriz C, Schramm U, Weinandi T. Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy. Neuromolecular Med 2007; 9: 340-54.
64. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000; 54: 2066-71.
65. Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 2006; 7: 78.
66. Alzheimer's Research Center. Current research. URL: http://www. alzheimersinfo.org.
67. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007; 86: 136-42.
68. Heese K, Low JW, Inoue N. Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals 2006-2007; 15: 1-12. (Pubitemid 44131419)
69. Prasad KN, Cole WC, Prasad KC. Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr 2002; 21: 506-22.
70. Ginkgo biloba and the brain. Brain Research Institute UCLA. 2006. URL: http://www.bri.ucla.edu/bri-weekly/news-060901.asp.
71. Bueno M, Bravo L, Cuadros A, Cárdenas W, De Romero CE, Gómez G, et al. Enfermedad de Alzheimer y estrógenos. Revista de Menopausia [online]. URL: http://www.encolombia.com/medicina/menopausia/ meno8102-contrienferm.htm.
72. Uetsuki T, Takemoto K, Nishimura I, Okamoto M, Niinobe M, Yoshikawa K, et al. Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amiloid precursor protein. J Neurosci 1999; 19: 6955-64.
73. Green KN, Martínez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27: 4385-95.
74. Xuan AG, Luo M, Ji WD, Long DH. Effects of engrafted neural stem cells in Alzheimer's disease rats. Neurosci Lett 2009; 450: 167-71.